Sponsor: Galera Therapeutics, Inc.
Protocol GTI-4419-301 (ROMAN): A phase 3 study to evaluate the efficacy of GC4419 in treating Oral Mucositis in patients with non-metastatic cancer of the oral cavity or oropharynx that are currently being treated with adjuvant, concurrent cisplatin and radiation.